Dark

BCRX
BioCryst Pharmaceuticals Inc
stock NASDAQ

At Close

May 9, 2025 3:59:58 PM EDT

9.96USD+0.403%(+0.04)7,607,126

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 9, 2025 9:28:30 AM EDT

9.96USD+0.403%(+0.04)7,580

After-hours

May 9, 2025 4:34:30 PM EDT

10.15USD+1.899%(+0.19)7,342

OverviewOptionsHistoricalExchangesShortsNews

Jan 12, 2022

01:11PM EST If You Invested $1000 In This Stock 10 Years Ago, Here's How Much You Would Have Today Benzinga

Jan 10, 2022

07:38AM EST BioCryst Expects Q4 Prelim. ORLADEYO Net Revenue Of $45.6M, FY21 ORLADEYO Net Revenue Of $122M Benzinga

07:00AM EST ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021 GlobeNewswire Inc

Jan 7, 2022

01:05PM EST BioCryst Reports Began Patient Enrollment In REDEEM-1 Trial Evaluating BCX9930 As Oral Monotherapy For Patients With Paroxysmal Nocturnal Hemoglobinuria Benzinga

09:25AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH). GlobeNewswire Inc

Jan 4, 2022

04:15PM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Monday, January 10, 2022 at 9:45 a.m. ET. GlobeNewswire Inc

Dec 10, 2021

12:41PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 Benzinga

05:08AM EST Oppenheimer Initiates Coverage On BioCryst Pharmaceuticals with Outperform Rating, Announces Price Target of $16 Benzinga

Dec 8, 2021

10:59AM EST BioCryst Pharmaceuticals Option Alert: Jun 17 $23 Calls Sweep (12) near the Ask: 400 @ $0.651 vs 1 OI; Ref=$12.30 Benzinga

Dec 7, 2021

07:53AM EST BioCryst Pharmaceuticals Granted U.S. Patent #11,192,861 'Human plasma kallikrein inhibitors' Benzinga

Dec 3, 2021

07:00AM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Nov 29, 2021

08:31AM EST BioCryst Begins Patient Enrollment In REDEEM-2 Pivotal Trial Evaluating BCX9930 As Oral Monotherapy For Patients With PNH Benzinga

08:30AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH). GlobeNewswire Inc

Nov 22, 2021

07:13AM EST Royalty Pharma Acquires Additional Royalty Interests In BCX9930 And ORLADEYO From BioCryst Pharmaceuticals Benzinga

07:10AM EST -- Provides funding for BCX9930/oral Factor D program across multiple indications -- Agreements supported by strength of ORLADEYO (berotralstat) launch and confidence in future opportunity GlobeNewswire Inc

07:00AM EST Provides funding for BCX9930/oral Factor D program across multiple indications GlobeNewswire Inc

Nov 12, 2021

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the following upcoming virtual investor conferences: GlobeNewswire Inc

Nov 5, 2021

09:39AM EDT BioCryst Highlights Presentation Of Data Showing Sustained Reduction Of HAE Attack Rates And Improved Patient Satisfaction After Patients Switch To ORLADEYO Benzinga

07:00AM EDT BioCryst Presents New Data Showing Sustained Reduction of HAE GlobeNewswire Inc

Nov 4, 2021

08:35AM EDT RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Lowers Price Target to $14 Benzinga

07:24AM EDT Barclays Maintains Overweight on BioCryst Pharmaceuticals, Lowers Price Target to $17 Benzinga

Nov 3, 2021

09:15AM EDT Biocryst Pharmaceuticals Sees FY21 ORLADEYO Sales $115M-$120M Benzinga

09:15AM EDT Biocryst Pharmaceuticals Q3 EPS $(0.33) Misses $(0.29) Estimate, Sales $41.00M Beat $39.38M Estimate Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

07:00AM EDT BioCryst Reports Third Quarter 2021 Financial Results and Upcoming GlobeNewswire Inc

Nov 2, 2021

07:00AM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Nov 1, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer. GlobeNewswire Inc

Oct 26, 2021

07:34AM EDT BioCryst To Present New ORLADEYO Data At Annual Scientific Meeting Of American College Of Allergy, Asthma & Immunology Nov. 4-8 Benzinga

07:00AM EDT BioCryst to Present New ORLADEYO (berotralstat) Data GlobeNewswire Inc

Oct 20, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021. GlobeNewswire Inc

Oct 4, 2021

07:29AM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

07:00AM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 30, 2021

11:21AM EDT BioCryst Pharmaceuticals Option Alert: Jan, 2024 $30 Calls Sweep (10) near the Ask: 70 @ $4.4 vs 2364 OI; Earnings 11/4 Before Open [est] Ref=$14.6602 Benzinga

Sep 21, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET. GlobeNewswire Inc

Sep 20, 2021

07:09AM EDT BioCryst Appoints Amy McKee To Board RTTNews

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), Amy McKee, M.D., to its board of directors. GlobeNewswire Inc

Sep 16, 2021

11:50AM EDT NICE Recommends BioCryst's Hereditary Angioedema Med Benzinga

Sep 15, 2021

08:20PM EDT NICE Recommends BioCrysts ORLADEYO GlobeNewswire Inc

Sep 9, 2021

07:22AM EDT BioCryst Announces Approval Of ORLADEYO In United Arab Emirates Benzinga

07:00AM EDT BioCryst Announces Approval of ORLADEYO (berotralstat) GlobeNewswire Inc

Sep 3, 2021

07:00AM EDT BioCryst to Present at Upcoming Investor Conferences GlobeNewswire Inc

Sep 2, 2021

04:01PM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 1, 2021

09:03AM EDT US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med Benzinga

07:09AM EDT BioCryst Pharmaceuticals Announces U.S. Department Of Health And Human Services Has Exercised Its Option To Purchase An Additional 10,000 Doses Of BioCryst's Antiviral Influenza Therapy, RAPIVAB, For ~$7M Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCrysts antiviral influenza therapy, RAPIVAB (peramivir injection), for approximately $7 million. GlobeNewswire Inc

Aug 26, 2021

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former acting surgeon general, Steven Galson, M.D., MPH to its board of directors. GlobeNewswire Inc

Aug 25, 2021

04:02PM EDT BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO (berotralstat) by Health Canada and Swissmedic Benzinga

04:01PM EDT BioCryst Announces Acceptance of Regulatory Applications for GlobeNewswire Inc

01:45PM EDT 'Benin confirms H5N1 avian flu outbreak' -Al Jazeera Report Benzinga

Aug 23, 2021

03:52PM EDT BioCryst Pharmaceuticals Option Alert: Jan 21 $20 Calls at the Ask: 300 @ $1.55 vs 6741 OI; Ref=$15.105 Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

10:40PM EDT BioCryst Pharmaceuticals Inc. (BCRX) said that it has withdrawn its proposed public offering. It believes that current market conditions are not conducive to an offering on terms that would be in the best interests of current stockholders. RTTNews

Aug 9, 2021

04:07PM EDT BioCryst Commences Public Offering Of $200M Of Common Stock And Pre-Funded Warrants Benzinga

04:01PM EDT BioCryst Commences Public Offering of Common Stock and Pre-Funded GlobeNewswire Inc

Aug 6, 2021

11:46AM EDT Jefferies Downgrades BioCryst Pharmaceuticals to Hold Benzinga

10:04AM EDT RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Raises Price Target to $16 Benzinga

09:29AM EDT JMP Securities Maintains Market Outperform on BioCryst Pharmaceuticals, Raises Price Target to $23 Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

07:42AM EDT Barclays Maintains Overweight on BioCryst Pharmaceuticals, Raises Price Target to $21 Benzinga

06:19AM EDT HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $30 Benzinga

Aug 5, 2021

07:09AM EDT Biocryst Pharmaceuticals Q2 EPS $(0.24), Inline, ORLADEYO Net Revenue $28.5M Benzinga

07:00AM EDT BioCryst Reports Second Quarter 2021 Financial Results and GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021 Benzinga

07:50AM EDT Cantor Fitzgerald Initiates Coverage On BioCryst Pharmaceuticals with Overweight Rating, Announces Price Target of $21 Benzinga

07:00AM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Jul 29, 2021

11:09AM EDT BioCryst Pharmaceuticals Option Alert: Aug 20 $17 Calls Sweep (9) near the Ask: 246 @ $1.3 vs 6782 OI; Earnings 8/5 Before Open Ref=$16.92 Benzinga

Jul 28, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors. GlobeNewswire Inc

Jul 22, 2021

11:35AM EDT BioCryst Pharmaceuticals Files For U.S. Patent Application Titled, 'SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS' Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2021 financial results on Thursday, August 5, 2021. GlobeNewswire Inc

Jul 15, 2021

09:42AM EDT BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder Benzinga

07:05AM EDT BioCryst Announces Designs For REDEEM-1 And REDEEM-2 Pivotal Trials With BCX9930 As Oral Monotherapy For Patients With PNH Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH). GlobeNewswire Inc

Jul 12, 2021

07:05AM EDT BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks Benzinga

Jul 10, 2021

10:02AM EDT BioCryst Reports 96-week Data from APeX-2 Showing GlobeNewswire Inc

Jul 1, 2021

04:18PM EDT BioCryst Pharmaceuticals Announces ORLADEYO Data To Be Presented At European Academy Of Allergy And Clinical Immunology Hybrid Congress Benzinga

04:15PM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress from July 10-12, 2021. GlobeNewswire Inc

Jun 22, 2021

10:59AM EDT BioCryst Pharmaceuticals Granted U.S. Patent Titled 'Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)' Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

07:51AM EDT BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema Benzinga

07:09AM EDT BioCryst Pharma: Israeli Ministry Of Health Accepts Regulatory Submission Of ORLADEYO RTTNews

07:04AM EDT BioCryst Announces Acceptance And Accelerated Review Of The ORLADEYO Marketing Application By The Israeli Ministry Of Health Benzinga

07:00AM EDT BioCryst Announces Acceptance and Accelerated Review of the GlobeNewswire Inc

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

Jun 9, 2021

10:27AM EDT China Reports Outbreak Of H5N8 Bird Flu In Wild Birds In Shaanxi Province Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 7, 2021

11:37AM EDT BioCryst Pharmaceuticals Option Alert: Jul 16 $20 Calls Sweep (17) near the Ask: 619 @ $0.75 vs 1197 OI; Earnings 8/5 Before Open [est] Ref=$17.17 Benzinga

Jun 4, 2021

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

Jun 3, 2021

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

07:19AM EDT BioCryst Launches ORLADEYO In Germany Benzinga

07:14AM EDT BioCryst Says Oral, Once-daily ORLADEYO Is Now Available For Patients With Prescription In Germany RTTNews

07:00AM EDT BioCryst Pharmaceuticals, Inc.(Nasdaq:BCRX) today announcedthat oral, once-daily ORLADEYO(berotralstat) is now available for patients with a prescription in Germany. GlobeNewswire Inc

May 28, 2021

08:02AM EDT The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq Benzinga

May 26, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET and the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:30 p.m. ET. Both are being conducted as virtual conferences. GlobeNewswire Inc

May 19, 2021

07:30AM EDT The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics Benzinga

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 17, 2021

09:50AM EDT BioCryst Pharmaceuticals Option Alert: Jun 18 $15 Calls Sweep (20) near the Ask: 400 @ $0.798 vs 6275 OI; Ref=$13.55 Benzinga

May 12, 2021

10:17AM EDT BioCryst Pharmaceuticals Inc. (BCRX) said Wednesday that it has received an approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency for its oral, once-daily Orladeyo or berotralstat for the routine prevention of recurrent hereditary angioedema or HAE attacks in HAE patients 12 years and older. RTTNews

09:36AM EDT BioCryst Says UK' MHRA Granted Marketing Authorization For Oral, Once-daily ORLADEYO RTTNews

09:26AM EDT BioCryst Pharmaceuticals Says Receives UK Approval Of ORLADEYO, First Oral, Once-Daily Therapy To Prevent Attacks In Hereditary Angiodema Patients Benzinga

09:25AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA)has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. GlobeNewswire Inc

May 6, 2021

02:00PM EDT BioCryst Pharma Shares Quiet As Hearing Evercore ISI Raised Price Target On Stock From $16 To New Street-High Target Of $20 Benzinga

12:32PM EDT BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:43AM EDT Biocryst Pharmaceuticals Q1 EPS $(0.36) Misses $(0.27) Estimate, Sales $19.10M Beat $8.89M Estimate Benzinga

07:00AM EDT BioCryst Reports First Quarter 2021 Financial Results and Upcoming GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m. ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET. Both are being conducted as virtual conferences. GlobeNewswire Inc

Apr 30, 2021

09:23AM EDT BioCryst Reports Receives European Commission Approval Of ORLADEYO To Prevent Attacks In Hereditary Angioedema Patients Benzinga

09:22AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. GlobeNewswire Inc

Apr 22, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021. GlobeNewswire Inc

Apr 15, 2021

12:19PM EDT Mid-Day Market Update: Dow Surges 250 Points; KLX Energy Services Shares Slide Benzinga

Apr 14, 2021

08:16AM EDT BioCryst Pharma Reports Approval Of Japanese National Health Insurance System Price Listing Of Its ORLADEYO For Hereditary Angioedema Benzinga

08:15AM EDT ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan GlobeNewswire Inc

Apr 7, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET. GlobeNewswire Inc

Mar 24, 2021

08:40AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:39AM EDT HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $19 Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

01:19PM EDT BioCryst Pharmaceuticals shares were trading higher ahead of the company's expected phase 1 clinical trial data for BCX9930. Benzinga

09:29AM EDT BioCryst To Start Pivotal BCX9930 Trial In Rare Blood Disorder In 2H'21 Benzinga

08:01AM EDT BioCryst's Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial Benzinga

08:00AM EDT Following doses of 400 mg bid or 500 mg bid of oral BCX9930, 100 percent of treatment-nave patients and 83 percent of C5 inadequate response patients were transfusion-free GlobeNewswire Inc

Mar 19, 2021

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly created position of chief research and development officer. GlobeNewswire Inc

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

03:31PM EDT BioCryst Pharmaceuticals Option Alert: Apr 16 $19 Calls Sweep (42) above Ask!: 889 @ $0.997 vs 4 OI; Earnings 5/5 Before Open [est] Ref=$13.51 Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will host a virtual R&D day on Monday, March 22, 2021 from 9:00 am to 11:00 am ET. GlobeNewswire Inc

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

08:36AM EST BioCryst Annonuces French National Agency For Medicines And Health Products Safety Has Granted Temporary Authorization For Use For Berotralstat Benzinga

08:30AM EST Early Access to BioCrysts Berotralstat Granted GlobeNewswire Inc

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 2, 2021

07:22AM EST BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema Benzinga

07:16AM EST BioCryst Submits MAA To UK's MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema RTTNews

07:00AM EST BioCryst Submits Marketing Authorization Application for UK GlobeNewswire Inc

05:16AM EST Biocryst Pharmaceuticals Awarded U.S. Patent 10,933,066 'Methods and compositions for treatment of Zika virus infection' Benzinga

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

06:31AM EST BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema Benzinga

Feb 25, 2021

05:31PM EST BioCryst Receives Positive CHMP Opinion for ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:34AM EST Biocryst Pharmaceuticals Q4 EPS $(0.34) Misses $(0.25) Estimate, Sales $4.02M Miss $17.52M Estimate Benzinga

07:00AM EST ORLADEYO (berotralstat) now approved in U.S. and Japan; EU approval expected in Q2 GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 21, 2021

05:11PM EST Russia on Saturday Reported First Case of Strain of Bird Flu Virus A(H5N8) being Passed to Humans from Birds Benzinga

Feb 18, 2021

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Cowen 41st Annual Healthcare Conference on Thursday, March 4, 2021 at 12:10 p.m. ET and the Barclays Annual Healthcare Conference on Thursday, March 11, 2021 at 8:00 a.m. ET. Both conferences are being held as virtual events. GlobeNewswire Inc

Feb 11, 2021

11:21AM EST BioCryst Pharma Shares Tick Slightly Higher On Volume As Traders Circulate European Patent Office Registration For Co.'s 'SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS' Benzinga

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. GlobeNewswire Inc

Feb 9, 2021

07:15AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO (berotralstat) will be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held virtually from February 26-March 1, 2021. GlobeNewswire Inc

Feb 3, 2021

12:24PM EST BioCryst shares were trading higher after the company announced FDA approval of its supplemental new drug application for RAPIVAB, expanding patient population to include children six months and older. Benzinga

08:36AM EST BioCryst Gains After FDA Nod For Expanded Use of RAPIVAB Benzinga

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

07:21AM EST BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB RTTNews

07:01AM EST BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB Expanding Patient Population to Include Children Six Months and Older Benzinga

07:00AM EST BioCryst Announces FDA Approval of Supplemental New Drug GlobeNewswire Inc

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

07:00AM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Jan 22, 2021

12:34PM EST BioCryst Pharmaceuticals shares were trading higher after the company announced the approval of ORLADEYO in Japan for prophylactic treatment of hereditary angioedema. Also, RBC Capital maintained a Sector Perform rating and raised its price target from $7 to $9. Benzinga

10:59AM EST Looking Into Biocryst Pharmaceuticals's Return On Capital Employed Benzinga

07:07AM EST RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Raises Price Target to $9 Benzinga

07:05AM EST BioCryst Secures Approval Of ORLADEYO In Japan RTTNews

07:03AM EST BioCryst Announces The Ministry of Health, Labor and Welfare In Japan Has Approved ORLADEYO for the Prophylactic Treatment of Hereditary Angioedema Benzinga

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. GlobeNewswire Inc

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

06:20AM EST China's Agriculture Ministry Reports Swine Fever Outbreak Reported in Guangdong Province Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 7, 2021

07:00AM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Jan 6, 2021

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET. GlobeNewswire Inc

Jan 2, 2021

10:46AM EST Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates Benzinga

Dec 22, 2020

08:26AM EST Amended: BioCryst Expects NIAID To Discontinue Pursuit Of A COVID-19 Indication For Galidesivir RTTNews

07:15AM EST BioCryst Pharmaceuticals, Inc. (BCRX) said, based on the ongoing discussions with the National Institute of Allergy and Infectious Diseases, the company expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir. RTTNews

07:08AM EST BioCryst To Discontinue Pursuit Of A COVID-19 Indication For Galidesivir RTTNews

07:07AM EST BioCryst Announces Data From Part 1 Of A Clinical Trial Of Galidesivir Showed That It Was Safe And Generally Well Tolerated In Patients Infected With SARS-CoV-2 Benzinga

07:00AM EST BioCryst Provides Update on Galidesivir Program GlobeNewswire Inc

Dec 21, 2020

07:22AM EST BioCryst Announces Positive Phase 1 Results With BCX9250 For Treatment Of Fibrodysplasia Ossificans Progressiva RTTNews

07:14AM EST BioCryst Announces Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva Was Safe And Well Tolerated At All Doses Studied Benzinga

07:00AM EST BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral GlobeNewswire Inc

Dec 16, 2020

07:12AM EST BioCryst Says ORLADEYO Is Now Available For Shipment To Patients With A Prescription In US RTTNews

07:02AM EST BioCryst Announces U.S. Availability of ORLADEYO for the Treatment of Hereditary Angioedema Benzinga

07:01AM EST Direct to patient shipments of the first oral, once-dailyprophylactic treatment underway through Optime Care GlobeNewswire Inc

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. GlobeNewswire Inc

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

08:51AM EST UPDATE: Royalty Pharma Has Acquired Royalty Interest In ORLADEYO And BCX9930 From BioCryst Pharmaceuticals; Will Pay BioCryst $125M Up Front And Will Receive 8.75% On Direct Annual Sales Of ORLADEYO Up To $350M, 2.75% On Sales $350M-$550M Benzinga

08:45AM EST Royalty Pharma(Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. GlobeNewswire Inc

08:42AM EST BioCryst Announces $325M Of Funding From Royalty Pharma And Athyrium Capital Management Benzinga

08:40AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. GlobeNewswire Inc

06:59AM EST HC Wainwright & Co. Maintains Buy on BioCryst Pharmaceuticals, Raises Price Target to $14 Benzinga

Dec 6, 2020

10:00AM EST Data presented at the 62nd American Society of Hematology Annual Meeting GlobeNewswire Inc

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 4, 2020

10:02AM EST Looking Into Biocryst Pharmaceuticals's Return On Capital Employed Benzinga

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

05:13AM EST BioCryst Announced Late Thursday FDA Approval of ORLADEYO to Prevent Attacks in Hereditary Angioedema Patients Benzinga

Dec 3, 2020

08:52PM EST BioCryst FDA Oks ORLADEYO, Oral, Once-daily Therapy To Prevent Attacks In Hereditary Angioedema Patients RTTNews

08:45PM EST BioCryst Announces FDA Approval of ORLADEYO GlobeNewswire Inc

04:49PM EST BioCryst Pharmaceuticals Shares Spike 10%; Hearing Mentions Of Incoming FDA Decision Benzinga

Dec 1, 2020

04:15PM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Nov 30, 2020

07:11AM EST BioCryst Highlights Publication Of Results From APeX-J Trial In Allergy Journal Benzinga

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the journal Allergy has published data from the APeX-J trial, a randomized, placebo-controlled trial conducted in Japan evaluating oral, once-daily berotralstat for the prophylactic treatment of hereditary angioedema (HAE). GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 24, 2020

09:51AM EST Benzinga's Top Upgrades, Downgrades For November 24, 2020 Benzinga

05:42AM EST Evercore ISI Group Initiates Coverage On BioCryst Pharmaceuticals with Outperform Rating, Announces Price Target of $12 Benzinga

Nov 23, 2020

04:08PM EST BioCryst Pharma Shares Higher After Hours; Hearing Evercore ISI Initiates With Outperform Rating, $12 Price Target Benzinga

Nov 20, 2020

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Evercore ISI 3rd Annual HealthCONx on Wednesday, December 2, 2020 at 12:35 p.m. ET and at the Piper Sandler 32nd Annual Healthcare Conference. Both conferences are being conducted as virtual events. GlobeNewswire Inc

Nov 13, 2020

07:59AM EST What Does BioCryst Pharmaceuticals's Debt Look Like? Benzinga

07:14AM EST BioCryst Presents New Clinical Data On Berotralstat In APeX-2 Trial RTTNews

07:14AM EST BioCryst Presents New Clinical Data Further Evaluating Attack Rate Reductions, Patient Satisfaction, Quality Of Life Of Hereditary Angioedema Patients In APeX-2 Trial Over 48 Weeks Benzinga

07:06AM EST BioCryst Highlights Presentation Of Data On 'Burden of Therapy with Current Injectable Prophylaxis Medication for HAE' Benzinga

07:02AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary angioedema (HAE) patients in the APeX-2 trial over 48 weeks. Berotralstat is an investigational treatment for the prevention of attacks in patients with HAE. GlobeNewswire Inc

07:00AM EST Data presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) GlobeNewswire Inc

Nov 12, 2020

07:40AM EST CORRECTION: Bioceres Crop Solutions Ticker Is BIOX Benzinga

07:38AM EST Bioceres Crop Solutions Corp. Acquires Full Ownership Of HB4 Soy And Strategic Intellectual Property Rights For Wheat From Arcadia Biosciences Benzinga

07:38AM EST Bioceres Crop Solutions Corp. Acquires Full Ownership Of HB4 Soy And Strategic Intellectual Property Rights For Wheat Benzinga

07:00AM EST BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology(ASH) Annual Meeting being held as a virtual event, December 5-8, 2020. GlobeNewswire Inc

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:07AM EST Biocryst Pharmaceuticals Q3 EPS $(0.26) Misses $(0.25) Estimate, Sales $6.10M Beat $3.60M Estimate Benzinga

07:00AM EST BioCryst Reports Third Quarter 2020 Financial Results GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

04:15PM EST BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

08:18AM EDT MHRA Grants HAE Patients Early Access To BioCryst's Berotralstat In United Kingdom Benzinga

08:15AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). GlobeNewswire Inc

Oct 28, 2020

07:27AM EDT Biocryst To Present Berotralsat Abstracts At Annual Scientific Meeting Of American College of Allergy, Asthma & Immunology Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts and one Distinguished Industry Oral Abstract at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November 13-15, which is being conducted as a virtual meeting. GlobeNewswire Inc

Oct 22, 2020

07:16AM EDT BioCryst Pharma Reports Data From First 24 Weeks Of APeX-2 Trial Of ORal, Once-Daily Berotralstrat In Patients With Hereditary Angioedema Published In Journal Of Allergy And Clinical Immunology Benzinga

07:00AM EDT Berotralstat significantly reduced HAE attack rates versus placebo over 24 weeks GlobeNewswire Inc

Oct 5, 2020

04:15PM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Sep 30, 2020

07:10AM EDT BioCryst Highlights Data Showing Its Oral Factor D Inhibitor, BCX9930, 'Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-nave PNH Patients' Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from treatment-nave (no prior treatment with C5 inhibitors) paroxysmal nocturnal hemoglobinuria (PNH) patients receiving doses through 400 mg bid of its oral Factor D inhibitor, BCX9930, as monotherapy in an ongoing dose-ranging trial. GlobeNewswire Inc

Sep 8, 2020

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 22nd annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET. The conference is being conducted as a virtual event. GlobeNewswire Inc

Sep 3, 2020

04:15PM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

07:13AM EDT BioCryst Pharmaceuticals Announces U.S. Department Of Health And Human Services Has Exercised Its Option To Purchase An Additional 10,000 Doses Of Its RAPIVAB For ~$7M Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCrysts approved antiviral influenza therapy, RAPIVAB (peramivir injection), for approximately $7 million. GlobeNewswire Inc

Aug 31, 2020

09:29AM EDT BioCryst Reports National Institute of Allergy and Infectious Diseases $44M Contract To Advance Development Of Galidesivir Benzinga

09:29AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling $44 million, and has added approximately $3 million to its existing contract (HHSN272201300017C), to support the development of galidesivir. GlobeNewswire Inc

07:12AM EDT BioCryst Pharma: FDA Grants Orphan Drug Designation For BCX9930 For Paroxysmal Nocturnal Hemoglobinuria RTTNews

07:01AM EDT BioCryst Pharma's Factor D Inhibitor BCX9930 is Granted Orphan Drug Designation by the FDA Benzinga

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). GlobeNewswire Inc

Aug 13, 2020

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

Aug 12, 2020

04:33PM EDT BioCryst Pharmaceuticals CFO Doyle Buys 54,000 Shares @$4.08/Share Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:00AM EDT ORLADEYO (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021 GlobeNewswire Inc

Aug 4, 2020

07:00AM EDT BioCryst Reports Inducement Grants Under Nasdaq Listing Rule GlobeNewswire Inc

Aug 3, 2020

07:22AM EDT BioCryst Receives Fast Track Designation For Its Oral Factor D Inhibitor, BCX9930 RTTNews

07:03AM EDT BioCryst Pharmaceuticals' Oral Factor D Inhibitor BCX9930 Granted Fast Track Designation by the FDA Benzinga

07:02AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). GlobeNewswire Inc

Jul 30, 2020

09:02AM EDT Cramer Weighs In On Lumber Liquidators, HCA Healthcare And More Benzinga

Jul 23, 2020

07:00AM EDT BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020. GlobeNewswire Inc